Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information

Share Article

Bernstein Liebhard LLP represents plaintiffs in federal Xarelto lawsuits, and this order will help ensure the preservation of evidence that may prove relevant to these cases.

Free Case Review
Our Firm is currently representing plaintiffs in federal Xarelto lawsuits, and we are pleased that this proceeding is moving forward.

Hundreds of federal Xarelto lawsuits (http://www.xareltolawsuit2015.com/) filed on behalf of individuals who allegedly experienced serious internal bleeding and other complications due to its use continue to move forward in the U.S. District Court, Eastern District of Louisiana. According to a Pretrial Order dated May 4, 2015, the Court has established procedures governing the preservation of documents and electronically stored information. Among other things, the Order sets forth preservation obligations for plaintiffs and defendants, as well as the acceptable methods of preservation. (In Re: Xarelto Products Liability Litigation, No. 2592)

“Our Firm is currently representing plaintiffs in federal Xarelto lawsuits, and we are pleased that this proceeding is moving forward. The procedures set forth in this order will help to ensure that any evidence which might prove relevant to these cases is preserved,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively filing Xarelto lawsuits in U.S. courts, and continues to evaluate claims on behalf of individuals who allegedly suffered a life-threatening internal bleeding episode, a stroke, deep vein thrombosis or pulmonary embolism due to their use of this blood thinner.

Xarelto Litigation
Court documents indicate that more than 430 Xarelto lawsuits have been filed in the multidistrict litigation underway in Louisiana, all of which allege that the drug’s manufacturers failed to provide adequate warnings regarding its association with serious side effects, including internal bleeding, strokes, deep vein thrombosis and pulmonary embolism. Among other things, plaintiffs cite allegedly misleading marketing claims which positioned Xarelto as a superior alternative to warfarin, a blood thinner that has been on the market for decades. The lawsuits point out that while hemorrhaging associated with warfarin can be stopped via the administration of vitamin K, there is currently no approved antidote to reverse Xarelto bleeding. Plaintiffs also assert that Xarelto users would benefit from regular blood monitoring, regardless of the manufacturers’ contention that monitoring is unnecessary.

In addition to the Xarelto lawsuits pending in the federal multidistrict litigation, at least 243 similar claims have been filed in a Pennsylvania mass tort litigation now underway in the Philadelphia Court of Common Pleas. (In Re: Xarelto Litigation, Case ID 150102349)

According to court documents, Xarelto was cleared for sale by the U.S. Food & Drug Administration in 2011, and is now approved for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. A black box warning on the Xarelto label includes information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.*

Individuals who allegedly experienced internal bleeding and other complications related to Xarelto may be entitled to compensation for their medical bills, lost wages, pain and suffering, and other damages. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.

*accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf, FDA, March 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.xareltolawsuit2015.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website